Determination of COVID-19 PCR positivity and mutation status in coronaVac vaccinated individuals in Turkey

Conclusions: In conclusion, people who receive two doses of CoronaVac vaccine can be reinfected with mutant viruses, vaccine significantly reduces the need for hospitalization, CT findings and intensive care.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Background/aim: CoronaVac is an inactivated virus-based COVID-19 vaccine used in Turkey and approved for emergency use by the World Health Organization (WHO).

📊

Key Findings & Data:In this study, it was aimed to retrospectively evaluate the mutation status and clinical status in individuals who received two doses of CoronaVac vaccine and were infected with COVID-19 at least two weeks after the second dose.

💡

Conclusion & Impact:Conclusions: In conclusion, people who receive two doses of CoronaVac vaccine can be reinfected with mutant viruses, vaccine significantly reduces the need for hospitalization, CT findings and intensive care.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Background/aim: CoronaVac is an inactivated virus-based COVID-19 vaccine used in Turkey and approved for emergency use by the World Health Organization (WHO). In this study, it was aimed to retrospectively evaluate the mutation status and clinical status in individuals who received two doses of CoronaVac vaccine and were infected with COVID-19 at least two weeks after the second dose. Materials and methods: 164 people were included in the study and COVID-19 diagnosis and mutation analyses were determined by RT-PCR using the Bioseepdy SARS CoV-2 Double Gene RT-qPCR Kit and the Biospeedy SARS-CoV-2 Variant Plus kit in accordance with the protocol determined by the manufacturer. Results: 116 (70.7%) UK (Alpha, B.1.1.7) mutation and 3 (1.8%) South Africa (Beta, B.1.351), Brazil (Gamma, P.1) mutations were determined in 164 double doses CoronaVac vaccinated patients; 45 (27.5%) patients were mutation negative. Nine patients (5.5%) developed pneumonia. Eight patients (4.9%) had CT findings compatible with corona virus infection. Seven (4.3%) of the patients received treatment in the intensive care unit, and 5 (3%) of the patients were intubated. Conclusions: In conclusion, people who receive two doses of CoronaVac vaccine can be reinfected with mutant viruses, vaccine significantly reduces the need for hospitalization, CT findings and intensive care.

🔖

Cite This Article

KALELI, İ., ÇALIŞKAN, A., DÖNMEZ, B., ÖNER, S. Z., SARI, T., YAKA, S. K., SEÇME, M. (2022). Determination of COVID-19 PCR positivity and mutation status in coronaVac vaccinated individuals in Turkey. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 3, 541–546. https://ajindex.com/articles/609246

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Weston S, Frieman MB. COVID-19: Knowns, Unknowns, and Questions. mSphere 2020;5(2):e00203-20. doi:10.1128/ mSphere.00203-20 2. Khan S, Siddique R, Shereen MA, Ali A, Liu J et al. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. Journal of clinical microbiology 2020;58(5): e00187-20. doi:10.1128/ JCM.00187-20 3. Wu A, Peng Y, Huang B, Ding X, Wang X et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 2020;11;27(3):325-328. doi: 10.1016/j.chom.2020.02.001 4. Maxmen A. One million coronavirus sequences: popular genome site hits mega milestone. Nature 2021;593(7857): 21. doi:10.1038/d41586-021-01069-w 5. Martin MA, VanInsberghe D, Koelle K. Insights from SARSCoV-2 sequences. Science 2021;371(6528): 466-467. doi:10.1126/ science.abf3995 6. Rahman M, Shirin T, Rahman S, Rahman MM, Hossain ME et al. The emergence of SARS-CoV-2 variants in Dhaka city, Bangladesh. Transboundary and Emerging Diseases 2021; 68(6): 3000-3001. doi: 10.1111/tbed.14203 7. Shen L, Bard JD, Triche TJ, Judkins AR, Biegel JA, Gai X. Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with spike protein D178H and membrane protein V70L mutations. Emerging Microbes & Infections 2021;10(1):1293- 1299. doi: 10.1080/22221751.2021.1943540 8. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD et al. Comprehensive mapping of mutations in the SARSCoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 2021; 29(3): 463– 476.e6. doi:10.1016/j. chom.2021.02.003 9. Jia Z, Gong W. Will Mutations in the Spike Protein of SARSCoV-2 Lead to the Failure of COVID-19 Vaccines? Journal of Korean Medical Science 2021; 10;36(18): e124. doi: 10.3346/ jkms.2021.36.e124 10. Di Caro A, Cunha F, Petrosillo N, Beeching NJ, Ergonul O et al. Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations. Clinical Microbiology and Infection 2021;27(6):823-826. doi: 10.1016/j.cmi.2021.03.011 11. Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y et al. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatology International 2021;41(8):1429-1440. doi: 10.1007/s00296-021-04910-7 12. Gao Q, Bao L, Mao H, Wang L, Xu K et al. Development of an inact